News

The study showed that the protein PUMA frees p53 from the grip of a third protein, Bcl-xL, so p53 can activate the series of signals that triggers programmed cell suicide.

The MDVN 300 compounds hold potential to help HRPC patients who currently face largely ineffective treatment options.

The combination of specimen preparation with LMPC and the mature kit technology from Qiagen enables the user to analyze specimens far more specifically and efficiently.

Patients with a specific combination of polymorphisms in genes responsible for the production of C-reactive protein (CRP) and interleukin-6 (IL-6) suffered stroke at three times higher rate.

RNAx provides Nucleis and its customers with in vitro shRNA validation technology to complement their proprietary transgenic animal generation technology, including the “Speedy Mouse® Technology” and vice versa.

This study generated two million short DNA sequences, known as signature sequences or sequence tags, to identify and quantify both known and novel small RNA molecules.

TaqMan® miRNA Assays can be used to differentiate _expression levels of miRNA molecules during embryonic stem cell differentiation.

Researchers based at EMBL headquarters will have access to the system as part of their daily research activities.

The patent application is being filed in conjunction with major research institutions in the Houston area, with Power3 having an exclusive license to commercialize the technology involved.

InforSense KDE, will provide Bayer with a flexible rapid application development platform to optimize their drug discovery decision-making.